Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/23.

Danuta M Skowronski,Hugues Charest,Samantha E Kaweski,Shinhye Kim,Suzana Sabaiduc,Romy Olsha,Jonathan B Gubbay,Gaston De Serres,Nathalie Bastien,Erica Sy Chuang,Nathan Zelyas,Agatha N Jassem,James A Dickinson

doi:10.2807/1560-7917.es.2023.28.5.2300043

Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/23.

Danuta M Skowronski, Hugues Charest + Show 11 more

Open Access

https://doi.org/10.2807/1560-7917.es.2023.28.5.2300043

Copy DOI

Journal: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin	Publication Date: Feb 2, 2023
Citations: 23	License type: CC BY 4.0

Affiliation: Institut National de Santé Publique du Québec, BC Centre for Disease Control, Public Health Ontario, University of Toronto, Centre Hospitalier Universitaire de Québec, Université Laval, Public Health Agency of Canada, Alberta Hospital Edmonton, University of British Columbia, University of Calgary

#Clade 3C #Early-season Influenza + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

The Canadian Sentinel Practitioner Surveillance Network estimated vaccine effectiveness (VE) during the unusually early 2022/23 influenza A(H3N2) epidemic. Like vaccine, circulating viruses were clade 3C.2a1b.2a.2, but with genetic diversity affecting haemagglutinin positions 135 and 156, and reassortment such that H156 viruses acquired neuraminidase from clade 3C.2a1b.1a. Vaccine provided substantial protection with A(H3N2) VE of 54% (95% CI: 38 to 66) overall. VE was similar against H156 and vaccine-like S156 viruses, but with potential variation based on diversity at position 135.

Full Text